

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Orbifloxacin Solid Formulation

Version 8.0 Revision Date: 12/06/2025 SDS Number: 801090-00020 Date of last issue: 04/14/2025
Date of first issue: 07/15/2016

SECTION 1. IDENTIFICATION

Product name : Orbifloxacin Solid Formulation

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc
Address : 126 E. Lincoln Avenue
Rahway, New Jersey U.S.A. 07065
Telephone : 908-740-4000
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product
Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Hazards for the product as supplied

Reproductive toxicity : Category 2

Other hazards

Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.

Hazards associated with a change in physical form:

| Conditions | Hazards |
|---|--|
| If small particles are generated during further processing, handling or by other means. | May form combustible dust concentrations in air. |

GHS label elements

Hazard pictograms : 

Signal Word : Warning

Hazard Statements : H361d Suspected of damaging the unborn child.

Precautionary Statements : **Prevention:**
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P280 Wear protective gloves, protective clothing, eye protection and face protection.

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Orbifloxacin Solid Formulation

Version 8.0 Revision Date: 12/06/2025 SDS Number: 801090-00020 Date of last issue: 04/14/2025
Date of first issue: 07/15/2016

Response:

P308 + P313 IF exposed or concerned: Get medical attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents and container to an approved waste disposal plant.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

| Chemical name | CAS No./Unique ID | Concentration (% w/w) | Trade secret |
|--------------------|-------------------|-----------------------|--------------|
| Orbifloxacin | 113617-63-3* | $\geq 5 - \leq 10$ | TSC |
| Magnesium stearate | 557-04-0* | $\geq 0.5 - \leq 1.5$ | TSC |

* Indicates that the identifier is a CAS No.

TSC- the actual concentration or concentration range is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.
- In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : Suspected of damaging the unborn child.
Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.
No information available.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Orbifloxacin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 04/14/2025 |
| 8.0 | 12/06/2025 | 801090-00020 | Date of first issue: 07/15/2016 |

||Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

- Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides
Nitrogen oxides (NO_x)
Metal oxides
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.
- Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Orbifloxacin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 04/14/2025 |
| 8.0 | 12/06/2025 | 801090-00020 | Date of first issue: 07/15/2016 |

employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

- | | | |
|-----------------------------|---|--|
| Technical measures | : | Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres. |
| Local/Total ventilation | : | Use only with adequate ventilation. |
| Advice on safe handling | : | Do not breathe dust. Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment. |
| Conditions for safe storage | : | Keep in properly labeled containers. Store locked up. Store in accordance with the particular national regulations. |
| Materials to avoid | : | Do not store with the following product types: Strong oxidizing agents |

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

| | |
|------------------------------|--|
| inert or nuisance dust | 50 Million particles per cubic foot Value type (Form of exposure): TWA (total dust) Basis: OSHA Z-3 |
| | 15 mg/m ³ Value type (Form of exposure): TWA (total dust) Basis: OSHA Z-3 |
| | 5 mg/m ³ Value type (Form of exposure): TWA (respirable fraction) Basis: OSHA Z-3 |
| | 15 Million particles per cubic foot Value type (Form of exposure): TWA (respirable fraction) Basis: OSHA Z-3 |
| Dust, nuisance dust and par- | 10 mg/m ³ |

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Orbifloxacin Solid Formulation

Version 8.0 Revision Date: 12/06/2025 SDS Number: 801090-00020 Date of last issue: 04/14/2025
Date of first issue: 07/15/2016

||| ticularates

Value type (Form of exposure): PEL (Total dust)
Basis: CAL PEL

|||

5 mg/m³
Value type (Form of exposure): PEL (respirable dust fraction)
Basis: CAL PEL

| Components | CAS-No. | Value type (Form of exposure) | Control parameters / Permissible concentration | Basis |
|--------------------|-------------|-------------------------------------|--|----------|
| Orbifloxacin | 113617-63-3 | TWA | 0.2 mg/m ³ (OEB 2) | Internal |
| Magnesium stearate | 557-04-0 | TWA (Inhalable particulate matter) | 10 mg/m ³ | ACGIH |
| | | TWA (Respirable particulate matter) | 3 mg/m ³ | ACGIH |

Engineering measures : Use feasible engineering controls to minimize exposure to compound.
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

Respiratory protection : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

Hand protection
Material

: Chemical-resistant gloves

Eye protection

: Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection
Hygiene measures

: Work uniform or laboratory coat.
: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Orbifloxacin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 04/14/2025 |
| 8.0 | 12/06/2025 | 801090-00020 | Date of first issue: 07/15/2016 |

Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

| | | |
|--|---|---|
| Appearance | : | powder |
| Color | : | No data available |
| Odor | : | No data available |
| Odor Threshold | : | No data available |
| pH | : | No data available |
| Melting point/freezing point | : | No data available |
| Initial boiling point and boiling range | : | No data available |
| Flash point | : | Not applicable |
| Evaporation rate | : | No data available |
| Flammability (solid, gas) | : | May form explosive dust-air mixture during processing, handling or other means. |
| Flammability (liquids) | : | No data available |
| Upper explosion limit / Upper flammability limit | : | No data available |
| Lower explosion limit / Lower flammability limit | : | No data available |
| Vapor pressure | : | No data available |
| Relative vapor density | : | No data available |
| Relative density | : | No data available |
| Density | : | No data available |
| Solubility(ies) Water solubility | : | No data available |
| Partition coefficient: n-octanol/water | : | No data available |
| Autoignition temperature | : | No data available |

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Orbifloxacin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 04/14/2025 |
| 8.0 | 12/06/2025 | 801090-00020 | Date of first issue: 07/15/2016 |

Decomposition temperature : No data available

Viscosity
Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics
Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg
Method: Calculation method

Components:

Orbifloxacin:

Acute oral toxicity : LD50 (Rat): > 3,000 mg/kg
Remarks: No mortality observed at this dose.

LD50 (Mouse): > 2,000 mg/kg

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Orbifloxacin Solid Formulation

Version 8.0 Revision Date: 12/06/2025 SDS Number: 801090-00020 Date of last issue: 04/14/2025
Date of first issue: 07/15/2016

Remarks: No mortality observed at this dose.
LD50 (Dog): > 600 mg/kg
Symptoms: Vomiting
Remarks: No mortality observed at this dose.

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of administration) : LD50 (Rat): > 200 mg/kg
Application Route: Intramuscular

LD50 (Mouse): 500 mg/kg
Application Route: Intramuscular

LD50 (Rat): 233 mg/kg
Application Route: Intravenous

LD50 (Mouse): 250 mg/kg
Application Route: Intravenous

Magnesium stearate:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 423
Assessment: The substance or mixture has no acute oral toxicity
Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg
Remarks: Based on data from similar materials

Skin corrosion/irritation

Not classified based on available information.

Components:

Orbifloxacin:

Species : Rabbit
Method : Draize Test
Result : No skin irritation

Magnesium stearate:

Species : Rabbit
Result : No skin irritation
Remarks : Based on data from similar materials

Serious eye damage/eye irritation

Not classified based on available information.

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Orbifloxacin Solid Formulation

Version 8.0 Revision Date: 12/06/2025 SDS Number: 801090-00020 Date of last issue: 04/14/2025
Date of first issue: 07/15/2016

Components:

Orbifloxacin:

Species : Rabbit
Result : Mild eye irritation
Method : Draize Test

Magnesium stearate:

Species : Rabbit
Result : No eye irritation
Remarks : Based on data from similar materials

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:

Orbifloxacin:

Test Type : Maximization Test
Routes of exposure : Dermal
Species : Guinea pig
Result : Not a skin sensitizer.

Magnesium stearate:

Test Type : Maximization Test
Routes of exposure : Skin contact
Species : Guinea pig
Method : OECD Test Guideline 406
Result : negative
Remarks : Based on data from similar materials

Germ cell mutagenicity

Not classified based on available information.

Components:

Orbifloxacin:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: equivocal

Test Type: Mouse Lymphoma
Result: positive

Test Type: Chromosomal aberration
Test system: Human lymphocytes
Result: positive

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Orbifloxacin Solid Formulation

Version 8.0 Revision Date: 12/06/2025 SDS Number: 801090-00020 Date of last issue: 04/14/2025
Date of first issue: 07/15/2016

Genotoxicity in vivo : Test Type: Micronucleus test
Species: Mouse
Cell type: Bone marrow
Application Route: Intraperitoneal injection
Result: negative

Test Type: unscheduled DNA synthesis assay
Species: Rat
Cell type: Liver cells
Application Route: Oral
Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Magnesium stearate:

Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test
Result: negative
Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: negative
Remarks: Based on data from similar materials

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Remarks: Based on data from similar materials

Carcinogenicity

Not classified based on available information.

Components:

Orbifloxacin:

Species : Rat
Application Route : Oral
Exposure time : 2 Years
NOAEL : 200 mg/kg body weight
Result : negative

Species : Mouse
Application Route : Oral
Exposure time : 2 Years
NOAEL : 200 mg/kg body weight
Result : negative

IARC No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Orbifloxacin Solid Formulation

Version 8.0 Revision Date: 12/06/2025 SDS Number: 801090-00020 Date of last issue: 04/14/2025
Date of first issue: 07/15/2016

Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat
Application Route: Ingestion
Result: negative
Remarks: Based on data from similar materials

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Not classified based on available information.

Repeated dose toxicity

Components:

Orbifloxacin:

Species : Rat
NOAEL : 20 mg/kg
LOAEL : 80 mg/kg
Application Route : Oral
Exposure time : 3 Months
Target Organs : Testis, Liver, Kidney, spleen

Species : Mouse
NOAEL : 80 mg/kg
LOAEL : 250 mg/kg
Application Route : Oral
Exposure time : 3 Months

Species : Juvenile dog
NOAEL : 50 mg/kg
LOAEL : 250 mg/kg
Application Route : Oral
Exposure time : 14 Days
Target Organs : Heart, Bone
Symptoms : Gastrointestinal disturbance
Remarks : mortality observed

Species : Juvenile dog
NOAEL : 2 mg/kg
LOAEL : 3 mg/kg
Application Route : Oral
Exposure time : 90 Days
Target Organs : Bone
Remarks : No significant adverse effects were reported

Species : Dog
NOAEL : 37.5 mg/kg
Application Route : Oral
Exposure time : 30 Days

Species : Cat

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Orbifloxacin Solid Formulation

Version 8.0 Revision Date: 12/06/2025 SDS Number: 801090-00020 Date of last issue: 04/14/2025
Date of first issue: 07/15/2016

NOAEL : 7.5 mg/kg
LOAEL : 22.5 mg/kg
Application Route : Oral
Exposure time : 1 Months
Symptoms : Gastrointestinal disturbance

Magnesium stearate:

Species : Rat
NOAEL : > 100 mg/kg
Application Route : Ingestion
Exposure time : 90 Days
Remarks : Based on data from similar materials

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Orbifloxacin:

Ingestion : Symptoms: central nervous system effects, Gastrointestinal disturbance, liver function change, anaphylaxis, Rash
Remarks: May cause photosensitization.

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Magnesium stearate:

Toxicity to fish : LC50 (Leuciscus idus (Golden orfe)): > 100 mg/l
Exposure time: 48 h
Method: DIN 38412
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates : EL50 (Daphnia magna (Water flea)): > 1 mg/l
Exposure time: 47 h
Test substance: Water Accommodated Fraction
Method: Directive 67/548/EEC, Annex V, C.2.
Remarks: Based on data from similar materials
No toxicity at the limit of solubility.

Toxicity to algae/aquatic plants : EL50 (Pseudokirchneriella subcapitata (green algae)): > 1 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials
No toxicity at the limit of solubility.

NOELR (Pseudokirchneriella subcapitata (green algae)): > 1

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Orbifloxacin Solid Formulation

Version 8.0 Revision Date: 12/06/2025 SDS Number: 801090-00020 Date of last issue: 04/14/2025
Date of first issue: 07/15/2016

mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials

Toxicity to microorganisms : EC10 (Pseudomonas putida): > 100 mg/l
Exposure time: 16 h
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials

Persistence and degradability

Components:

Magnesium stearate:

Biodegradability : Result: Not biodegradable
Remarks: Based on data from similar materials

Bioaccumulative potential

Components:

Magnesium stearate:

Partition coefficient: n-octanol/water : log Pow: > 4

Mobility in soil

No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Dispose of in accordance with local regulations.
Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Orbifloxacin Solid Formulation

Version 8.0 Revision Date: 12/06/2025 SDS Number: 801090-00020 Date of last issue: 04/14/2025
Date of first issue: 07/15/2016

Transport in bulk according to IMO instruments

Not applicable for product as supplied.

Domestic regulation

49 CFR

Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : Reproductive toxicity

SARA 313 : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations

Pennsylvania Right To Know

| | |
|---|-------------|
| D-Glucose, 4-O-β-D-galactopyranosyl-, monohydrate | 64044-51-5 |
| Orbifloxacin | 113617-63-3 |
| Polyvinyl pyrrolidone | 9003-39-8 |
| Starch, carboxymethyl ether, sodium salt | 9063-38-1 |

California List of Hazardous Substances

| | |
|-----------------------|-----------|
| Polyvinyl pyrrolidone | 9003-39-8 |
|-----------------------|-----------|

California Permissible Exposure Limits for Chemical Contaminants

| | |
|--------------------|----------|
| Magnesium stearate | 557-04-0 |
|--------------------|----------|

The ingredients of this product are reported in the following inventories:

AICS : not determined

CA. DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION

Further information

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Orbifloxacin Solid Formulation


Version
8.0

Revision Date:
12/06/2025

SDS Number:
801090-00020

Date of last issue: 04/14/2025
Date of first issue: 07/15/2016

NFPA 704:



HMIS® IV:

| | | |
|-----------------|---|---|
| HEALTH | * | 0 |
| FLAMMABILITY | | 3 |
| PHYSICAL HAZARD | | 0 |

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

| | | |
|----------------|---|---|
| ACGIH | : | USA. ACGIH Threshold Limit Values (TLV) |
| CAL PEL | : | California permissible exposure limits for chemical contaminants (Title 8, Article 107) |
| OSHA Z-3 | : | USA. Occupational Exposure Limits (OSHA) - Table Z-3 Mineral Dusts |
| ACGIH / TWA | : | 8-hour, time-weighted average |
| CAL PEL / PEL | : | Permissible exposure limit |
| OSHA Z-3 / TWA | : | 8-hour time weighted average |

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardization; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECS - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organization for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic sub-

SAFETY DATA SHEET

according to the OSHA Hazard Communication Standard



Orbifloxacin Solid Formulation

| | | | |
|---------|----------------|--------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 04/14/2025 |
| 8.0 | 12/06/2025 | 801090-00020 | Date of first issue: 07/15/2016 |

stance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorization and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 12/06/2025

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8